No Data
No Data
ARS Pharmaceuticals to Showcase Innovation and Present Data on Neffy (Epinephrine Nasal Spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting
Oppenheimer Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $40
ARS Pharmaceuticals Initiated With an Outperform at Oppenheimer
Oppenheimer Initiates ARS Pharmaceuticals at Outperform
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
Express News | ARS Pharmaceuticals Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing